Unveiling the role of nuclear transport in epithelial-to-Mesenchymal transition

Current Cancer Drug Targets

Volumn 13, Issue 9, 2013, Pages 906-914

  Azmi, Asfar S ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CRM1; EMT; Epithelial to mesenchymal transition; Exportin; Importin; Karyopherin; Nuclear Transport; Xpo1

Indexed keywords

BETA CATENIN; EPIDERMAL GROWTH FACTOR; EXPORTIN 1; GREEN FLUORESCENT PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KARYOPHERIN; LEPTOMYCIN B; NOTCH RECEPTOR; PROTEIN P53; SMAD PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN; VIMENTIN;

APOPTOSIS; CELL PROLIFERATION; CELLULAR DISTRIBUTION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; MOLECULAR DOCKING; NONHODGKIN LYMPHOMA; NUCLEAR EXPORT SIGNAL; NUCLEAR PORE COMPLEX; PANCREAS CANCER; PHOSPHORYLATION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TRANSPORT AT THE CELLULAR LEVEL; WNT SIGNALING PATHWAY; ZINC FINGER MOTIF;

ACTIVE TRANSPORT, CELL NUCLEUS; CARRIER PROTEINS; CELL NUCLEUS; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; SIGNAL TRANSDUCTION;

EID: 84890844835     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/15680096113136660096     Document Type: Review

References (102)

1. Nakaya, Y.; Sheng, G. EMT in developmental morphogenesis. Cancer Lett. 2013, pii: S0304-3835(13)00163-8.
2. De, C. B.; Berx, G. Regulatory networks defining EMT during cancer initiation and progression. Nat. Rev. Cancer 2013, 13, 97-110.
3. Savagner, P. Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays 2001, 23, 912-923.
4. Sanchez-Tillo, E.; Liu, Y.; de, B. O.; Siles, L.; Fanlo, L.; Cuatrecasas, M.; Darling, D. S.; Dean, D. C.; Castells, A.; Postigo, A. EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness. Cell Mol. Life Sci. 2012, 69, 3429-3456.
5. Lee, M.; Goodbourn, S. Signalling from the cell surface to the nucleus. Essays Biochem. 2001, 37, 71-85.
6. Gorlich, D.; Laskey, R. A. Roles of importin in nuclear protein import. Cold Spring Harb. Symp. Quant. Biol. 1995, 60, 695-699.
7. Gorlich, D.; Mattaj, I. W. Nucleocytoplasmic transport. Science 1996, 271, 1513-1518.
8. Gorlich, D. Nuclear protein import. Curr. Opin. Cell Biol. 1997, 9, 412-419.
9. Gorlich, D. Transport into and out of the cell nucleus. EMBO J. 1998, 17, 2721-2727.
10. Gorlich, D.; Kutay, U. Transport between the cell nucleus and the cytoplasm. Annu. Rev. Cell Dev. Biol. 1999, 15, 607-660.
11. Turner, J. G.; Dawson, J.; Sullivan, D. M. Nuclear export of proteins and drug resistance in cancer. Biochem. Pharmacol. 2012, 83, 1021-1032.
12. Turner, J. G.; Sullivan, D. M. CRM1-mediated nuclear export of proteins and drug resistance in cancer. Curr. Med. Chem. 2008, 15, 2648-2655.
13. Moreno-Bueno, G.; Portillo, F.; Cano, A. Transcriptional regulation of cell polarity in EMT and cancer. Oncogene 2008, 27, 6958-6969.
14. Wu, Y.; Zhou, B. P. Snail: More than EMT. Cell Adh. Migr. 2010, 4, 199-203.
15. Peinado, H.; Olmeda, D.; Cano, A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat. Rev. Cancer 2007, 7, 415-428.
16. Chakrabarti, R.; Hwang, J.; Andres, B. M.; Wei, Y.; Lukacisin, M.; Romano, R. A.; Smalley, K.; Liu, S.; Yang, Q.; Ibrahim, T.; Mercatali, L.; Amadori, D.; Haffty, B. G.; Sinha, S.; Kang, Y. Elf5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2. Nat. Cell Biol. 2012, 14, 1212-1222.
17. Mulholland, D. J.; Kobayashi, N.; Ruscetti, M.; Zhi, A.; Tran, L. M.; Huang, J.; Gleave, M.; Wu, H. Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res. 2012, 72, 1878-1889.
18. Alves, C. C.; Carneiro, F.; Hoefler, H.; Becker, K. F. Role of the epithelial-mesenchymal transition regulator Slug in primary human cancers. Front Biosci. 2009, 14, 3035-3050.
19. Herfs, M.; Hubert, P.; Suarez-Carmona, M.; Reschner, A.; Saussez, S.; Berx, G.; Savagner, P.; Boniver, J.; Delvenne, P. Regulation of p63 isoforms by Snail and slug transcription factors in human squamous cell carcinoma. Am. J. Pathol. 2010, 176, 1941-1949.
20. Katoh, Y.; Katoh, M. Hedgehog signaling pathway and gastrointestinal stem cell signaling network (review). Int. J. Mol. Med. 2006, 18, 1019-1023.
21. Katoh, Y.; Katoh, M. Hedgehog signaling, epithelial-tomesenchymal transition and miRNA (review). Int. J. Mol. Med. 2008, 22, 271-275.
22. Maier, H. J.; Schmidt-Strassburger, U.; Huber, M. A.; Wiedemann, E. M.; Beug, H.; Wirth, T. NF-kappaB promotes epithelialmesenchymal transition, migration and invasion of pancreatic carcinoma cells. Cancer Lett. 2010, 295, 214-228.
23. Huber, M. A.; Beug, H.; Wirth, T. Epithelial-mesenchymal transition: NF-kappaB takes center stage. Cell Cycle 2004, 3, 1477-1480.
24. Huber, M. A.; Azoitei, N.; Baumann, B.; Grunert, S.; Sommer, A.; Pehamberger, H.; Kraut, N.; Beug, H.; Wirth, T. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J. Clin. Invest. 2004, 114, 569-581.
25. Vlahopoulos, S. A.; Logotheti, S.; Mikas, D.; Giarika, A, Gorgoulis, V.; Zoumpourlis, V. The role of ATF-2 in oncogenesis. Bioessays, 2008, 30, 314-327.
26. Anastas, J. N.; Moon, R. T. WNT signalling pathways as therapeutic targets in cancer. Nat. Rev. Cancer 2013, 13, 11-26.
27. Talbot, L. J.; Bhattacharya, S. D.; Kuo, P. C. Epithelialmesenchymal transition, the tumor microenvironment, and metastatic behavior of epithelial malignancies. Int. J. Biochem. Mol. Biol. 2012, 3, 117-136.
28. Sahlgren, C.; Gustafsson, M. V.; Jin, S.; Poellinger, L.; Lendahl, U. Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc. Natl. Acad. Sci. USA 2008, 105, 6392-6397.
29. Chang, C. J.; Chao, C. H.; Xia, W.; Yang, J. Y.; Xiong, Y.; Li, C. W.; Yu, W. H.; Rehman, S. K.; Hsu, J. L.; Lee, H. H.; Liu, M.; Chen, C. T.; Yu, D.; Hung, M. C. p53 regulates epithelialmesenchymal transition and stem cell properties through modulating miRNAs. Nat. Cell Biol. 2011, 13, 317-323.
30. Xu, D.; Farmer, A.; Chook, Y. M. Recognition of nuclear targeting signals by Karyopherin-beta proteins. Curr. Opin. Struct. Biol. 2010, 20, 782-790.
31. Chook, Y. M.; Suel, K. E. Nuclear import by karyopherin-betas: recognition and inhibition. Biochim. Biophys. Acta 2011, 1813, 1593-1606.
32. Fornerod, M.; Ohno, M. Exportin-mediated nuclear export of proteins and ribonucleoproteins. Results Probl. Cell Differ. 2002, 35, 67-91.
33. Cook, A. G.; Conti, E. Nuclear export complexes in the frame. Curr. Opin. Struct. Biol. 2010, 20, 247-252.
34. Marelli, M.; Dilworth, D. J.; Wozniak, R. W.; Aitchison, J. D. The dynamics of karyopherin-mediated nuclear transport. Biochem. Cell Biol. 2001, 79, 603-612.
35. Yoneda, Y. Nuclear pore-targeting complex and its role on nuclear protein transport. Arch. Histol. Cytol. 1996, 59, 97-107.
36. Marfori, M.; Lonhienne, T. G.; Forwood, J. K.; Kobe, B. Structural basis of high-affinity nuclear localization signal interactions with importin-alpha. Traffic 2012, 13, 532-548.
37. Forwood, J. K.; Lange, A.; Zachariae, U.; Marfori, M.; Preast, C.; Grubmuller, H.; Stewart, M.; Corbett, A. H.; Kobe, B. Quantitative structural analysis of importin-beta flexibility: paradigm for solenoid protein structures. Structure 2010, 18, 1171-1183.
38. Kutay, U.; Guttinger, S. Leucine-rich nuclear-export signals: born to be weak. Trends Cell Biol. 2005, 15, 121-124.
39. Guttler, T.; Gorlich, D. Ran-dependent nuclear export mediators: a structural perspective. EMBO J. 2011, 30, 3457-3474.
40. van der Watt, P. J.; Maske, C. P.; Hendricks, D. T.; Parker, M. I.; Denny, L.; Govender, D.; Birrer, M. J.; Leaner, V. D. The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int. J. Cancer 2009, 124, 1829-1840.
41. Becker, K. F.; Rosivatz, E.; Blechschmidt, K.; Kremmer, E.; Sarbia, M.; Hofler, H. Analysis of the E-cadherin repressor Snail in primary human cancers. Cells Tissues Organs 2007, 185, 204-212.
42. Dominguez, D.; Montserrat-Sentis, B.; Virgos-Soler, A.; Guaita, S.; Grueso, J.; Porta, M.; Puig, I.; Baulida, J.; Franci, C.; Garcia de, H. A. Phosphorylation regulates the subcellular location and activity of the Snail transcriptional repressor. Mol. Cell Biol. 2003, 23, 5078-5089.
43. Yamasaki, H.; Sekimoto, T.; Ohkubo, T.; Douchi, T.; Nagata, Y.; Ozawa, M.; Yoneda, Y. Zinc finger domain of Snail functions as a nuclear localization signal for importin beta-mediated nuclear import pathway. Genes Cells 2005, 10, 455-464.
44. Morrison, C. D.; Parvani, J. G.; Schiemann, W. P. The relevance of the TGF-beta Paradox to EMT-MET programs. Cancer Lett. 2013, pii: S0304-3835(13)00211-5.
45. Caja, L.; Bertran, E.; Campbell, J.; Fausto, N.; Fabregat, I. The transforming growth factor-beta (TGF-beta) mediates acquisition of a mesenchymal stem cell-like phenotype in human liver cells. J. Cell Physiol. 2011, 226, 1214-1223.
46. Pera, M. F.; Tam, P. P. Extrinsic regulation of pluripotent stem cells. Nature 2010, 465, 713-720.
47. Clarke, D. C.; Liu, X. Decoding the quantitative nature of TGFbeta/ Smad signaling. Trends Cell Biol. 2008, 18, 430-442.
48. Heldin, C. H.; Miyazono, K.; Ten, D. P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997, 390, 465-471.
49. Xiao, Z.; Watson, N.; Rodriguez, C.; Lodish, H. F. Nucleocytoplasmic shuttling of Smad1 conferred by its nuclear localization and nuclear export signals. J. Biol. Chem. 2001, 276, 39404-39410.
50. Xiao, Z.; Brownawell, A. M.; Macara, I. G.; Lodish, H. F. A novel nuclear export signal in Smad1 is essential for its signaling activity. J. Biol. Chem. 2003, 278, 34245-34252.
51. Xiao, Z.; Liu, X.; Lodish, H. F. Importin beta mediates nuclear translocation of Smad 3. J. Biol. Chem. 2000, 275, 23425-23428.
52. Xiao, Z.; Liu, X.; Henis, Y. I.; Lodish, H. F. A distinct nuclear localization signal in the N terminus of Smad 3 determines its ligand-induced nuclear translocation. Proc. Natl. Acad. Sci. USA 2000, 97, 7853-7858.
53. Watanabe, M.; Masuyama, N.; Fukuda, M.; Nishida, E. Regulation of intracellular dynamics of Smad4 by its leucine-rich nuclear export signal. EMBO Rep. 2000, 1, 176-182.
54. Moustakas, A.; Souchelnytskyi, S.; Heldin, C. H. Smad regulation in TGF-beta signal transduction. J. Cell Sci. 2001, 114, 4359-4369.
55. Kurisaki, A.; Kose, S.; Yoneda, Y.; Heldin, C. H.; Moustakas, A. Transforming growth factor-beta induces nuclear import of Smad3 in an importin-beta1 and Ran-dependent manner. Mol. Biol. Cell, 2001, 12, 1079-1091.
56. Dai, F.; Lin, X.; Chang, C.; Feng, X. H. Nuclear export of Smad2 and Smad3 by RanBP3 facilitates termination of TGF-beta signaling. Dev. Cell, 2009, 16, 345-357.
57. Itoh, S.; Landstrom, M.; Hermansson, A.; Itoh, F.; Heldin, C. H.; Heldin, N. E.; Ten, D. P. Transforming growth factor beta1 induces nuclear export of inhibitory Smad7. J. Biol. Chem. 1998, 273, 29195-29201.
58. Hill, C. S. Nucleocytoplasmic shuttling of Smad proteins. Cell Res., 2009, 19, 36-46.
59. Chen, H. B.; Rud, J. G.; Lin, K.; Xu, L. Nuclear targeting of transforming growth factor-beta-activated Smad complexes. J. Biol. Chem. 2005, 280, 21329-21336.
60. Tian, X.; Liu, Z.; Niu, B.; Zhang, J.; Tan, T. K.; Lee, S. R.; Zhao, Y.; Harris, D. C.; Zheng, G. E-cadherin/beta-catenin complex and the epithelial barrier. J. Biomed. Biotechnol. 2011, 2011, 567305.
61. Cadigan, K. M.; Waterman, M. L. TCF/LEFs and Wnt signaling in the nucleus. Cold Spring Harb. Perspect. Biol. 2012, 4(11), pii: a007906.
62. Cadigan, K. M. TCFs and Wnt/beta-catenin signaling: more than one way to throw the switch. Curr. Top. Dev. Biol. 2012, 98, 1-34.
63. Chang, M. V.; Chang, J. L.; Gangopadhyay, A.; Shearer, A.; Cadigan, K. M. Activation of wingless targets requires bipartite recognition of DNA by TCF. Curr. Biol. 2008, 18, 1877-1881.
64. Blauwkamp, T. A.; Chang, M. V.; Cadigan, K. M. Novel TCFbinding sites specify transcriptional repression by Wnt signalling. EMBO J. 2008, 27, 1436-1446.
65. Conacci-Sorrell, M.; Simcha, I.; Ben-Yedidia, T.; Blechman, J.; Savagner, P.; Ben-Ze'ev, A. Autoregulation of E-cadherin expression by cadherin-cadherin interactions: the roles of betacatenin signaling, Slug, and MAPK. J. Cell Biol. 2003, 163, 847-857.
66. Onder, T. T.; Gupta, P. B.; Mani, S. A.; Yang, J.; Lander, E. S.; Weinberg, R. A. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res. 2008, 68, 3645-3654.
67. Ayyanathan, K.; Peng, H.; Hou, Z.; Fredericks, W. J.; Goyal, R. K.; Langer, E. M.; Longmore, G. D.; Rauscher, F. J. The Ajuba LIM domain protein is a corepressor for SNAG domain mediated repression and participates in nucleocytoplasmic Shuttling. Cancer Res. 2007, 67, 9097-9106.
68. Langer, E. M.; Feng, Y.; Zhaoyuan, H.; Rauscher, F. J. 3rd; Kroll, K. L.; Longmore, G. D. Ajuba LIM proteins are Snail/slug corepressors required for neural crest development in Xenopus. Dev. Cell 2008, 14, 424-436.
69. Fagotto, F.; Gluck, U.; Gumbiner, B. M. Nuclear localization signal-independent and importin/karyopherin-independent nuclear import of beta-catenin. Curr. Biol. 1998, 8, 181-190.
70. Wang, Z.; Li, Y.; Banerjee, S.; Sarkar, F. H. Exploitation of the Notch signaling pathway as a novel target for cancer therapy. Anticancer Res. 2008, 28, 3621-3630.
71. Wang, Z.; Li, Y.; Banerjee, S.; Sarkar, F. H. Emerging role of Notch in stem cells and cancer. Cancer Lett. 2009, 279, 8-12.
72. Wang, Z.; Li, Y.; Kong, D.; Banerjee, S.; Ahmad, A.; Azmi, A. S.; Ali, S.; Abbruzzese, J. L.; Gallick, G. E.; Sarkar, F. H. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabineresistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 2009, 69, 2400-2407.
73. Wang, Z.; Li, Y.; Kong, D.; Sarkar, F. H. The role of Notch signaling pathway in epithelial-mesenchymal transition (EMT) during development and tumor aggressiveness. Curr. Drug Targets 2010, 11, 745-751.
74. Saad, S.; Stanners, S. R.; Yong, R.; Tang, O.; Pollock, C. A. Notch mediated epithelial to mesenchymal transformation is associated with increased expression of the Snail transcription factor. Int. J. Biochem. Cell Biol. 2010, 42, 1115-1122.
75. Timmerman, L. A.; Grego-Bessa, J.; Raya, A.; Bertran, E.; Perez-Pomares, J. M.; Diez, J.; Aranda, S.; Palomo, S.; McCormick, F.; Izpisua-Belmonte, J. C.; de la Pompa, J. L. Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. Genes Dev. 2004, 18, 99-115.
76. Matsuno, Y.; Coelho, A. L.; Jarai, G.; Westwick, J.; Hogaboam, C. M. Notch signaling mediates TGF-beta1-induced epithelialmesenchymal transition through the induction of Snai1. Int. J. Biochem. Cell Biol. 2012, 44, 776-789.
77. Bao, B.; Wang, Z.; Ali, S.; Kong, D.; Li, Y.; Ahmad, A.; Banerjee, S.; Azmi, A. S.; Miele, L.; Sarkar, F. H. Notch-1 induces epithelialmesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett. 2011, 307, 26-36.
78. Tekotte, H.; Davis, I. Intracellular mRNA localization: motors move messages. Trends Genet. 2002, 18, 636-642.
79. Huenniger, K.; Kramer, A.; Soom, M.; Chang, I.; Kohler, M.; Depping, R.; Kehlenbach, R. H.; Kaether, C. Notch1 signaling is mediated by importins alpha 3, 4, and 7. Cell Mol. Life Sci. 2010, 67, 3187-3196.
80. Schmidt, J.; Braggio, E.; Kortuem, K. M.; Egan, J. B.; Zhu, Y. X.; Xin, C. S.; Tiedemann, R. E.; Palmer, S. E.; Garbitt, V. M.; McCauley, D.; Kauffman, M.; Shacham, S.; Chesi, M.; Bergsagel, P. L.; Stewart, A. K. Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276. Leukemia 2013. [Epub ahead of print]
81. Salas Fragomeni, R. A.; Chung, H. W.; Landesman, Y.; Senapedis, W.; Saint-Martin, J. R.; Tsao, H.; Flaherty, K. T.; Shacham, S.; Kauffman, M.; Cusack, J. C. CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF mutant melanoma. Mol. Cancer Ther. 2013, 12(7), 1171-1179.
82. Tai, Y. T.; Landesman, Y.; Acharya, C.; Calle, Y.; Zhong, M. Y.; Cea, M.; Tannenbaum, D.; Cagnetta, A.; Reagan, M.; Munshi, A. A.; Senapedis, W.; Saint-Martin, J. R.; Kashyap, T.; Shacham, S.; Kauffman, M.; Gu, Y.; Wu, L.; Ghobrial, I.; Zhan, F.; Kung, A. L.; Schey, S. A.; Richardson, P.; Munshi, N. C.; Anderson, K. C. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia 2013. [Epub ahead of print]
83. Etchin, J.; Sanda, T.; Mansour, M. R.; Kentsis, A.; Montero, J.; Le, B. T.; Christie, A. L.; McCauley, D.; Rodig, S. J.; Kauffman, M.; Shacham, S.; Stone, R.; Letai, A.; Kung, A. L.; Thomas, L. A. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br. J. Haematol. 2013, 161, 117-127.
84. Inoue, H.; Kauffman, M.; Shacham, S.; Landesman, Y.; Yang, J.; Evans, C. P.; Weiss, R. H. CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth. J. Urol. 2013, 189, 2317-2326.
85. Kalid, O.; Toledo, W. D.; Shechter, S.; Sherman, W.; Shacham, S. Consensus Induced Fit Docking (cIFD): methodology, validation, and application to the discovery of novel Crm1 inhibitors. J. Comput. Aided Mol. Des. 2012, 26, 1217-1228.
86. Lapalombella, R.; Sun, Q.; Williams, K.; Tangeman, L.; Jha, S.; Zhong, Y.; Goettl, V.; Mahoney, E.; Berglund, C.; Gupta, S.; Farmer, A.; Mani, R.; Johnson, A. J.; Lucas, D.; Mo, X.; Daelemans, D.; Sandanayaka, V.; Shechter, S.; McCauley, D.; Shacham, S.; Kauffman, M.; Chook, Y. M.; Byrd, J. C. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood, 2012, 120, 4621-4634.
87. Zhang, K.; Wang, M.; Tamayo, A. T.; Shacham, S.; Kauffman, M.; Lee, J.; Zhang, L.; Ou, Z.; Li, C.; Sun, L.; Ford, R. J.; Pham, L. V. Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma. Exp. Hematol. 2013, 41, 67-78.
88. Etchin, J.; Sun, Q.; Kentsis, A.; Farmer, A.; Zhang, Z. C.; Sanda, T.; Mansour, M. R.; Barcelo, C.; McCauley, D.; Kauffman, M.; Shacham, S.; Christie, A. L.; Kung, A. L.; Rodig, S. J.; Chook, Y. M.; Look, A. T. Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells. Leukemia 2013, 27, 66-74.
89. Ranganathan, P.; Yu, X.; Na, C.; Santhanam, R.; Shacham, S.; Kauffman, M.; Walker, A.; Klisovic, R.; Blum, W.; Caligiuri, M.; Croce, C. M.; Marcucci, G.; Garzon, R. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood 2012, 120, 1765-1773.
90. Yoshida, M.; Nishikawa, M.; Nishi, K.; Abe, K.; Horinouchi, S.; Beppu, T. Effects of leptomycin B on the cell cycle of fibroblasts and fission yeast cells. Exp. Cell Res. 1990, 187, 150-156.
91. Hamamoto, T.; Seto, H.; Beppu, T. Leptomycins A and B, new antifungal antibiotics. II. Structure elucidation. J. Antibiot. (Tokyo), 1983, 36, 646-650.
92. Hamamoto, T.; Gunji, S.; Tsuji, H.; Beppu, T. Leptomycins A and B, new antifungal antibiotics. I. Taxonomy of the producing strain and their fermentation, purification and characterization. J. Antibiot.(Tokyo), 1983, 36, 639-645.
93. Hamamoto, T.; Uozumi, T.; Beppu, T. Leptomycins A and B, new antifungal antibiotics. III. Mode of action of leptomycin B on Schizosaccharomyces pombe. J. Antibiot.(Tokyo), 1985, 38, 1573-1580.
94. Nishi, K.; Yoshida, M.; Fujiwara, D.; Nishikawa, M.; Horinouchi, S.; Beppu, T. Leptomycin B targets a regulatory cascade of crm1, a fission yeast nuclear protein, involved in control of higher order chromosome structure and gene expression. J. Biol. Chem. 1994, 269, 6320-6324.
95. Sasaki, H.; Yoshida, M.; Beppu, T. Leptomycin B-induced fixation of X-ray-related potentially lethal damage. Radiat. Res. 1992, 129, 163-170.
96. Newlands, E. S.; Rustin, G. J.; Brampton, M. H. Phase I trial of elactocin. Br. J. Cancer 1996, 74, 648-649.
97. Mutka, S. C.; Yang, W. Q.; Dong, S. D.; Ward, S. L.; Craig, D. A.; Timmermans, P. B.; Murli, S. Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res. 2009, 69, 510-517.
98. Muqbil, I.; Kauffman, M.; Shacham, S.; Mohammad, R. M.; Azmi, A. S. Understanding XPO1 Target Networks Using Systems Biology and Mathematical Modeling. Curr. Pharm. Des. 2013. [Epub ahead of print].
99. Azmi, A. S.; Al-Katib, A.; Aboukameel, A.; McCauley, D.; Kauffman, M.; Shacham, S.; Mohammad, R. M. Selective inhibitors of nuclear export for the treatment of non-Hodgkin's Lymphomas. Haematologica 2013, 98(7), 1098-1106.
100. Azmi, A. S.; Aboukameel, A.; Bao, B.; Sarkar, F. H.; Philip, P. A.; Kauffman, M.; Shacham, S.; Mohammad, R. M. Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice. Gastroenterology 2013, 144, 447-456.
101. Kim, K., Lu, Z., and Hay, E.D. Direct evidence for a role of betacatenin/ LEF-1 signaling pathway in induction of EMT. Cell Biol. Int. 2002, 26, 463-476.
102. Kim, K.; Hay, E. D. New evidence that nuclear import of endogenous beta-catenin is LEF-1 dependent, while LEF-1 independent import of exogenous beta-catenin leads to nuclear abnormalities. Cell Biol. Int. 2001, 25, 1149-1161.